Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer
Clinical trial NCT03419559 · WITHDRAWN
Trial details
- NCT number
- NCT03419559
- Sponsor
- Iovance Biotherapeutics, Inc.
- Status
- WITHDRAWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-02-28
- Primary completion
- 2021-12-01
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.